Measurable Residual Disease-Guided Therapy Promising in CLL ...Middle East

Medscape - News
The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities. Medscape Medical News

Hence then, the article about measurable residual disease guided therapy promising in cll was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Measurable Residual Disease-Guided Therapy Promising in CLL )

Apple Storegoogle play

Last updated :

Also on site :